We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Blood Test Helps Identify Patients with Alzheimer's Associated Amyloid Pathology

By LabMedica International staff writers
Posted on 31 Jan 2025

Neurological diseases, such as Alzheimer's disease, are becoming an increasing cause of death and disability among older adults worldwide, posing significant challenges to healthcare systems. These conditions are complex and diverse, presenting a range of symptoms that complicate diagnosis. To address these challenges, a new blood test has been developed to help healthcare providers detect amyloid pathology associated with Alzheimer’s disease.

The Access p‑Tau217/β-Amyloid 1-42 plasma ratio, developed by Beckman Coulter Diagnostics (Brea, CA, USA), is a blood test that measures the ratio of phosphorylated tau protein (p-Tau217) and β‑Amyloid 1-42, both of which are key biomarkers involved in the neurodegenerative processes of Alzheimer's disease. This blood-based in vitro diagnostic (IVD) test is capable of quantifying these biomarkers in plasma, providing a non-invasive, accessible, and earlier method to detect Alzheimer’s-related pathology. Early detection is crucial for improving diagnosis, enabling timely interventions, and identifying patients for therapeutic trials, all of which can help accelerate progress in Alzheimer’s research and treatment. The Access p‑Tau217/β-Amyloid 1-42 plasma ratio has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

"We are honored to receive Breakthrough Device Designation from the U.S. FDA for our p‑Tau217/β-Amyloid 1-42 assay, a significant step forward in addressing the urgent need for earlier and more accurate detection of Amyloid pathology, a hallmark of Alzheimer's disease," said Kathleen Orland, Senior Vice President, General Manager, Clinical Chemistry and Immunoassay for Beckman Coulter Diagnostics. "This designation reflects the potential of our test to transform how Alzheimer's disease is diagnosed and managed, ultimately leading to improved outcomes for patients and families affected by this devastating disease."

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA Extraction Kit
Ron’s Gel Extraction Mini Kit
New
QC Software Solution
Unity Interlaboratory Program
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.